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Abstract
Background and Aims: Initial reports on US COVID-19 showed different outcomes in different races. In this study we
use a diverse large cohort of hospitalized COVID-19 patients to determine predictors of mortality.
Methods: We analyzed data from hospitalized COVID-19 patients (n = 5852) between March 2020- August 2020 from
8 hospitals across the US. Demographics, comorbidities, symptoms and laboratory data were collected.
Results: The cohort contained 3,662 (61.7%) African Americans (AA), 286 (5%) American Latinx (LAT), 1,407 (23.9%),
European Americans (EA), and 93 (1.5%) American Asians (AS). Survivors and non-survivors mean ages in years were
58 and 68 for AA, 58 and 77 for EA, 44 and 61 for LAT, and 51 and 63 for AS. Mortality rates for AA, LAT, EA and AS were
14.8, 7.3, 16.3 and 2.2%. Mortality increased among patients with the following characteristics: age, male gender, New
York region, cardiac disease, COPD, diabetes mellitus, hypertension, history of cancer, immunosuppression, elevated
lymphocytes, CRP, ferritin, D-Dimer, creatinine, troponin, and procalcitonin. Use of mechanical ventilation (p = 0.001),
shortness of breath (SOB) (p < 0.01), fatigue (p = 0.04), diarrhea (p = 0.02), and increased AST (p < 0.01), significantly
correlated with death in multivariate analysis. Male sex and EA and AA race/ethnicity had higher frequency of
death. Diarrhea was among the most common GI symptom amongst AAs (6.8%). When adjusting for comorbidities,
significant variables among the demographics of study population were age (over 45 years old), male sex, EA, and
patients hospitalized in New York. When adjusting for disease severity, significant variables were age over 65 years old,
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male sex, EA as well as having SOB, elevated CRP and D-dimer. Glucocorticoid usage was associated with an increased
risk of COVID-19 death in our cohort.
Conclusion: Among this large cohort of hospitalized COVID-19 patients enriched for African Americans, our study
findings may reflect the extent of systemic organ involvement by SARS-CoV-2 and subsequent progression to multisystem organ failure. High mortality in AA in comparison with LAT is likely related to high frequency of comorbidities
and older age among AA. Glucocorticoids should be used carefully considering the poor outcomes associated with
it. Special focus in treating patients with elevated liver enzymes and other inflammatory biomarkers such as CRP,
troponin, ferritin, procalcitonin, and D-dimer are required to prevent poor outcomes.
Keywords: COVID-19, SARS CoV-2, African American, Hispanic, Race, Ethnicity, Mortality, Hospitalized

Introduction
By April, 2022, the SARS-CoV-2 virus that causes
COVID-19 had infected 79 million Americans and
led to over 976,516 deaths[1]. The United States is one
of the most ethnically and racially diverse countries
in the world encompassing 13.4% African Americans
(AA) and 18.5% Latinos/Latinas (LAT) [1]. Disparities
among various ethnic groups span many aspects
of health [2–4], and specific racial/ethnic minority
populations have been disproportionately affected by
the morbidity and mortality related to COVID-19 [5–7].
Reports across the US indicate that African American
and Hispanic populations have higher COVID-19
related hospitalization and mortality than Caucasians.
Nationwide, AA have died at 1.4 times the rate of white
people [8, 9]. The presence of racial and ethnic disparities
in COVID-19 morbidity and mortality is partly due to
abiding economic and educational disadvantages that
have culminated in decreased healthcare utilization
and prevalent distrust of the healthcare system among
minority individuals [10].
A contributory cause for such a disproportionate
impact of COVID-19 in AA and LAT racial/ethnic
minority populations may be the higher prevalence of
chronic conditions or comorbidities when compared
to European Americans (EA) [6, 11, 12]. Members
of these ethnic/racial groups may disproportionately
hold occupations that do not permit adequate physical
distancing, increasing the potential for environmental
infection and transmission is enhanced [13]. The
majority of the AA and LAT are essential workers/
frontline workers who need to work in person and are
at even higher risk of contracting COVID-19. There
may also be differences in the provisions of hospital care
by racial/ethnic groups [4, 12], but there has not been
adequate data on hospital outcomes by race or ethnicity
that adjusts for potential confounders. Four major
reasons may explain the higher risk for COVID-19, Age,
co-morbidities (such as diabetes, obesity, hypertension,
cardiovascular Asthma, chronic obstructive pulmonary
disease (COPD), and chronic kidney disease), access to

health care and social economic status particularly for
minority[4, 12, 14]. The race and ethnicities to be strong
risk factors for infection and COVID-19 includes those of
African descent and Native Americans[12, 14].
In this study, we examined a hospitalized SARSCoV-2-positive cohort data enriched for AA including
gastrointestinal symptoms, clinical markers, and
comorbidities from 8 hospitals nationwide to determine
COVID-19 mortality predictors.

Materials and methods
Patient selection

In this retrospective study we collected de-identified
data and reviewed anthropometric, clinical, serum
laboratory tests and outcomes data of 5852 COVID-19
patients hospitalized at eight institutions in the United
States between March 2020- August 2020. This study
was approved by Howard University Institutional Review
Board (IRB) and the respective IRBs of all participating
centers [except data from Albert Einstein College of
Medicine, Bronx, NY where data was accessed [15]
after clarifications provided by the authors. An excel file
template was shared with our collaborators to streamline
and homogenize the process of data collection and
database construction. The total number of patients
included in this study was 5,852. However, the total
number for each variable in overall analysis varies due to
the missing values.
Inclusion and exclusion criteria

The following inclusion criteria were used to select
patients and studies that were involved in our analysis:
confirmed diagnosis of SARS-CoV-2 by PCR and
hospitalized for COVID-19, without restrictions based
on number of patients, and without distinction on
sex, age, treatment, manifestations, comorbidities, or
outcomes. Exclusion criteria included: studies where
the cohort did not include AA or LAT patients, studies
from outside of the US, studies where the cases were not
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confirmed by PCR, studies with incomplete symptoms
and comorbidities, and those with overlapping data.
Selected studies

De-identified data was obtained from 8 centers: Phoebe
Putney Health System in Southwest Georgia (SWG)
from March 2-May 6, 2020), Interfaith Medical Center,
Brooklyn (NYK) from March 1-April 9, 2020, Harlem
Hospital Columbia University (NYM) during March
and April 2020, Providence Community Health Centers
(RIH) from March 19-April 29, 2020, Montefiore Medical
Center in Bronx (NYB) from March 1-April 12, 2020;
Large academic institutions served as a referral center
and enrolled patients into local COVID-19 databases,
including for the state of Indiana (Indiana University
School of Medicine, IUM) from March 1-March 31, 2020,
Henry Ford Hospital Detroit (HFD) from March 7-April
30, 2020, and Howard University Hospital (HUH) from
February 28-August 9, 2020.
Database creation and data homogenization

From the selected studies, we obtained individually
de-identified data. We created tables containing the
following information: study author (location, hospital
or city and state), date of the report, location, confirmed
cases, deaths, age, symptoms (fever, chest pain, cough,
shortness of breath, abdominal pain, anorexia, diarrhea,
nausea, vomiting, fatigue, headache), comorbidities
(cardiac disease, coronary artery disease, asthma,
diabetes mellitus, hypertension, immunocompromised
status, cancer and alcohol intake), laboratory clinical
values (sodium, potassium, blood urea nitrogen
(BUN), creatinine, hemoglobin, lymphocyte count,
CPK, C-Reactive Protein (CRP), D-dimer, troponin,
ferritin, liver function enzymes, and procalcitonin),
and treatment (Hydroxychloroquine, Glucocorticoid,
Intubation/Mechanical ventilation and outcome (alive or
dead). For laboratory clinical values, reference laboratory
values were used to determine normal from abnormal
values (Low and High values), such as for lymphopenia
and lymphocytosis. All data were coded to streamline for
the statistical analysis. The collected data were checked,
cross validated for data completeness and accuracy and
amended in unlikely cases of error, by contacting the data
collectors and revisiting patient charts.
Statistical analysis

Patient
demographics,
symptoms,
underlying
comorbidities, treatment, and outcomes were compared
among AA, EA, LAT, and other ethnic groups. Predictors
of hospital mortality were evaluated by using logistic
and/or multiple logistic regression using four models to
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assess the effect of each risk factor: OR1: no adjustment;
OR2: adjusted for gender, age, ethnicity, and center; OR3:
the OR2 model further adjusted for comorbidities; and
OR4: the OR3 model further adjusted for disease severity.
Center was treated as independent categorical variable
with 8 categories and fitted to the logistic regression
model as a categorical variable. Regression models were
controlled for disease severity by including the indicators
of disease severity such as shortness of breath, CRP, and
D-dimer in the logistic regression model as independent
variables. In each analysis, odds ratios (ORs) and
associated 95% confidence intervals were calculated.
The 95% confidence interval was investigated to see if it
contains unity. Confidence intervals that included one
were considered not statistically significant.

Results
Overall and race‑specific mortality

Our study collected data from 5,858 patients from 8
different hospitals/centers across the United States
of whom 5,448 had data available on race/ethnicity
(Table 1). Of the total cohort, 3,662 (62.6%) patients were
AA, 1,407 (24%) were EA, 286 (5%) were LAT, and 93
(1.6%) were Asian Americans (AS). The overall mortality
rate was 14.5% (795 deaths) for all groups combined.
The mortality rates varied by racial group: 14.8% for
AA, 16.3% for EA, 7.3% for LAT and 2.2% for AS. There
were substantial differences in age and sex distribution
across these racial groups. The median age (in years) was
61 for AA, 62 for EA, 43 for LAT, and 51 for AS. After
adjusting for age, sex, and center, the OR (95% CI) for
mortality, compared to AA, was 1.35 (1.11–1.64) for EA,
0.97 (0.56–1.66) for LAT, and 0.25 (0.06–1.04) for AS
(Table 2). After adjusting for comorbidities and disease
severity, the differences remained.
Hypertension was the most frequent comorbidity
among all races

The frequency and percentages for comorbidities,
presenting symptoms, laboratory findings, and
treatments for all patients were analyzed by race
(Table 1). The most common comorbidities were
hypertension (57.7%), diabetes mellitus (34.1%), cardiac
disease (13.1%), COPD (9.8%), asthma (9.8%), history
of cancer (8.4%) and immunosuppression (5.3%).
Hypertension was the most common comorbidity in all
races (65% in AA, 45.8% in EA, 30.7% in LAT and 34.4%
in AS) followed by diabetes mellitus (39% in AA, 24.6%
in EA, 22.8% in LAT and 22.6 in AS). Overall, AA had
the highest prevalence of comorbidities over other races/
ethnicities.
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Table 1 Demographics, Clinical Manifestations and Comorbidities of COVID-19 patients
African-Americans

European-Americans

Latin-Americans

Asian-Americans

Discharge status, demographic and anthropometric indices
Discharge status (n = 5448)
Alive (n = 4653)

Dead (n = 795)

Sex (n = 5449)

Female (n = 2892)

Male (n = 2557)

Age (n = 5449)

(Median, interquartile range)
BMI (n = 5074)

Normal (n = 1174)

Overweight (n = 1321)

Obese (n = 2579)

Admitting center (n = 5450)

3662

1407

286

93

3120 (85.2)

1177 (83.7)

265 (92.7)

91 (97.8)

542 (14.8)

230 (16.3)

21 (7.3)

2 (2.2)

1936 (52.9)

735 (52.2)

119 (41.5)

40 (43)

1726 (47.1)

672 (47.8)

168 (58.5)

53 (57)

3663

1407

287

93

(61, 49, 71)

(62, 48, 78)

(43, 30 58)

(51, 40.5, 63)

699 (19.8)

388 (40.3)

60 (40.3)

27 (33.8)

863 (24.4)

378 (28.9)

48 (32.2)

32 (40)

1976 (55.9)

541 (41.4)

41 (27.5)

21 (26.3)

Michigan-Detroit

2040 (55.7)

1172 (83.3)

14 (4.9)

74 (79.6)

NY-New York

466 (12.7)

0 (0)

0 (0)

0 (0)

Indiana

90 (2.5)

37 (2.6)

7 (2.4)

5 (5.4)

Rhode Island

0 (0)

0 (0)

105 (36.6)

0 (0)

NY-Bronx

102 (2.8)

69 (4.9)

0 (0)

0 (0)

NY-Manhattan

114 (3.1)

1 (0.1)

58 (20.2)

11 (11.8)

DC-Howard

257 (7)

26 (1.8)

103 (35.9)

1 (1.1)

Georgia

594 (16.2)

102 (7.2)

0 (0)

2 (2.2)

Baseline comorbidities
Cardiac disease (n = 4142)

2379 (86.2)

1040 (86.9)

105 (95.5)

72 (96)

Yes (n = 546)

No (n = 3596)

381 (13.8)

157 (13.1)

5 (4.5)

3 (4)

No (n = 4144)

2673 (90.9)

1208 (87.5)

173 (94)

90 (97.8)

267 (9.1)

173 (12.5)

11 (6)

2 (2.2)

COPD (n = 4597)
Yes (n = 453)

Asthma (n = 4353)
No (n = 3923)

Yes (n = 430)

Diabetes mellitus (n = 5440)
No (n = 3583)

Yes (n = 1857)

Hypertension (n = 5437)
No (n = 2296)

Yes (n = 3141)

History of cancer (n = 4308)
No (n = 3945)

Yes (n = 363)

Immune suppression (n = 1948)
No (n = 1843)

Yes (n = 105)

2534 (88.9)

1240 (92.3)

67 (93.1)

82 (94.3)

316 (11.1)

104 (7.7)

5 (6.9)

5 (5.7)

2234 (61)

1060 (75.4)

217 (77.2)

72 (77.4)

1426 (39)

346 (24.6)

64 (22.8)

21 (22.6)

1279 (35)

762 (54.2)

194 (69.3)

61 (65.6)

2379 (65)

644 (45.8)

86 (30.7)

32 (34.4)

2610 (92.4)

1235 (89.5)

20 (95.2)

80 (98.8)

216 (7.6)

145 (10.5)

1 (4.8)

1 (1.2)

1420 (94.4)

214 (92.2)

201 (98.5)

8 (100)

84 (5.6)

18 (7.8)

3 (1.5)

0 (0)

Presenting symptoms
Fever (n = 5443)
No (n = 3811)

Yes (n = 1632)

Headache (n = 4274)

2471 (67.5)

1141 (81.2)

130 (45.6)

69 (74.2)

1188 (32.5)

265 (18.8)

155 (54.4)

24 (25.8)
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Table 1 (continued)
African-Americans
No (n = 4109)

Yes (n = 165)

Cough (n = 5260)
No (n = 3709)

Yes (n = 1551)

Shortness of breath (n = 5156)
No (n = 3147)

Yes (n = 2009)

Chest pain (n = 4308)
No (n = 4125)

Yes (n = 183)

Fatigue (n = 4696)
No (n = 4281)

Yes (n = 415)

Nausea (n = 4966)
No (n = 4694)

Yes (n = 272)

Vomiting (n = 4978)
No (n = 4798)

Yes (n = 180)

Abdominal pain (n = 5130)
No (n = 4950)

Yes (n = 180)

Diarrhea (n = 4637)
No (n = 4322)

Yes (n = 315)

Anorexia (n = 5113)
No (n = 4853)

Yes (n = 260)

European-Americans

Latin-Americans

Asian-Americans

2662 (97.3)

1317 (98.1)

56 (47.1)

74 (97.4)

74 (2.7)

26 (1.9)

63 (52.9)

2 (2.6)

2395 (67.6)

1153 (82)

94 (41.4)

67 (81.7)

1150 (32.4)

253 (18)

133 (58.6)

15 (18.3)

2056 (57.9)

966 (68.8)

62 (51.2)

63 (76.8)

1492 (42.1)

439 (31.2)

59 (48.8)

19 (23.2)

2704 (95.7)

1321 (95.7)

19 (90.5)

81 (100)

122 (4.3)

59 (4.3)

2 (9.5)

0 (0)

2905 (89.6)

1234 (95.4)

68 (80)

74 (97.4)

336 (10.4)

60 (4.6)

17 (20)

2 (2.6)

3202 (93.4)

1303 (97.7)

108 (90)

81 (98.8)

228 (6.6)

31 (2.3)

12 (10)

1 (1.2)

3293 (95.8)

1312 (98.2)

113 (91.9)

80 (97.6)

144 (4.2)

24 (1.8)

10 (8.1)

2 (2.4)

3402 (96.2)

1311 (98.3)

145 (86.8)

92 (98.9)

135 (3.8)

22 (1.7)

22 (13.2)

1 (1.1)

2833 (92.6)

1251 (95.9)

152 (84)

86 (94.5)

228 (7.4)

53 (4.1)

29 (16)

5 (5.5)

3322 (94.4)

1307 (98.1)

137 (80.6)

87 (93.5)

196 (5.6)

25 (1.9)

33 (19.4)

6 (6.5)

Laboratory results (Median, interquartile range)
Hemoglobin (n = 2903)

Normal (n = 1158, 39.9)

Low (n = 1712, 59)

Elevated (n = 33, 1.1)

Lymphocyte count (n = 3965)
Normal (n = 1627, 41)

Low (n = 2276, 57.4)

Elevated (n = 62, 1.6)

CPK (n = 1897)

Normal (n = 982, 51.8)

Elevated (n = 915, 48.2)

CRP (n = 2980)

Normal (n = 187, 6.3)

Elevated (n = 2793, 93.7)

D-Dimer (n = 2679)

Normal (n = 449, 16.8)

1872

967

20

44

712 (38)

415 (42.9)

13 (65)

18 (40.9)

1135 (60.6)

544 (56.3)

7 (35)

26 (59.1)

25 (1.3)

8 (0.8)

0 (0)

0 (0)

1187 (43.8)

354 (32.5)

67 (56.3)

19 (41.3)

1480 (54.6)

724 (66.5)

45 (37.8)

27 (58.7)

44 (1.6)

11 (1)

7 (5.9)

0 (0)

499 (42.8)

455 (65.8)

10 (90.9)

18 (62.1)

666 (57.2)

237 (34.2)

1 (9.1)

11 (37.9)

132 (6.6)

30 (3.6)

23 (21.3)

2 (5.7)

1880 (93.4)

795 (96.4)

85 (78.7)

33 (94.3)

275 (15.6)

146 (18.6)

20 (20)

8 (22.2)

Elevated (n = 2230, 83.2)

1484 (84.4)

638 (81.4)

80 (80)

28 (77.8)

Normal (n = 1845, 64.4)

1197 (63.5)

582 (64.8)

35 (81.4)

31 (75.6)

Troponin (n = 2867)
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Table 1 (continued)

Elevated (n = 1022, 35.6)

Procalcitonin (n = 2941)

Normal (n = 1408, 47.9)

Elevated (n = 1533, 52.1)

Ferritin (n = 2914)

Normal (n = 862, 29.6)

Low (n = 31, 1.1)

Elevated (n = 2021, 69.4)

LDH (n = 726)

Normal (n = 154, 21.2)

Elevated (n = 572, 78.8)

AST (n = 3356)

Normal (n = 1498 (44.6)

Elevated (n = 1858, 55.4)

ALT (n = 2760)

Normal (n = 2412, 87.4)

Elevated (n = 348, 12.6)

African-Americans

European-Americans

Latin-Americans

Asian-Americans

688 (36.5)

316 (35.2)

8 (18.6)

10 (24.4)

879 (43.8)

466 (59.4)

46 (40)

17 (53.1)

1130 (56.2)

319 (40.6)

69 (60)

15 (46.9)

511 (25.9)

314 (39)

28 (28.6)

9 (24.3)

19 (1)

11 (11.4)

0 (0)

1 (2.7)

1443 (73.1)

481 (59.7)

70 (71.4)

27 (73)

113 (19.9)

40 (33.6)

0 (0)

1 (16.7)

454 (80.1)

79 (66.4)

34 (100)

5 (83.3)

996 (44.3)

433 (46.9)

55 (39)

14 (31.8)

1251 (55.7)

491 (53.1)

86 (61)

30 (68.2)

1533 (88.4)

767 (90.7)

81 (58.3)

31 (75.6)

201 (11.6)

79 (9.3)

58 (41.7)

10 (24.4)

Interventions

Glucocorticoids (n = 3419)
No (n = 1703)

Yes (n = 1716)

Mechanical Ventilation (n = 4944)
No (n = 4262)

Yes (n = 682)

1249 (51.3)

364 (42.3)

82 (81.2)

8 (33.3)

1184 (48.7)

497 (57.7)

19 (18.8)

16 (66.7)

2816 (84.1)

1162 (89.5)

212 (96.8)

72 (93.5)

533 (15.9)

137 (10.5)

7 (3.2)

5 (6.5)

*The total number for each variable in overall columns may not be the same due to missing/not collected values. CAD coronary artery disease

Shortness of Breath (SOB) was the most frequent
presenting symptoms among all races

The most common presenting symptoms were
shortness of breath (38.9%), cough (29.4%%), and fever
(29.9%). The main GI symptoms were diarrhea (6.7%),
nausea (5.4%), vomiting (3.6%), and abdominal pain
(3.5%). Overall diarrhea was the most common GI
symptom among all the races (7.4% in AA, 4.1% in EA,
16% in LAT and 5.5% in AS) followed by nausea (6.6%
in AA, 2.3% in EA, 10% in LAT and 1.2% in AS) except
for LAT where the second most common symptom was
abdominal pain (13.2%) and AS for whom vomiting
was second (2.4%). In aggregate, LAT patients had
the highest prevalence of symptoms over other races/
ethnicities.
Inflammatory serum markers were commonly elevated
among all races

Measurements of systemic inflammation, such as CRP,
D-dimer, procalcitonin, and ferritin were elevated in the
majority of hospitalized COVID-19 patients irrespective
of race/ethnicity (Table 1). Other commonly affected

laboratory values included: presence of anemia and
lymphocytopenia, elevated CPK and troponin, elevated
LDH, and elevated AST but not ALT. Among races/
ethnicities, AA had the highest prevalence of increased
serum inflammatory markers.
Predictors of mortality

Age was a very strong predictor of mortality
from
COVID-19
(Table
2).
Compared
to
individuals < 35
years
of
age,
those
who
were >  = 75 years were at substantially higher risk of
death with an OR2 (95% CI) of 10.13 (6.40–16.0). This
association remained strong even after adjustment
for baseline comorbidities, with OR3 (95% CI) of
7.43 (4.64–11.89). Other demographic predictors of
mortality were male sex (OR2 = 1.48, 1.26–1.74) and
EA background (OR2 = 1.35, 1.11–1.64) and patients
in New York (OR2: 3.78, 2.94–4.86) compared to other
geographic locations. Several baseline comorbidities
were associated with increased risk of death, including
presence of cardiac disease (OR = 1.55, 1.22–1.96),
COPD (OR = 1.62, 1.25–2.08), or diabetes mellitus
(OR = 1.59, 1.26–1.75), and use of immunosuppression
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Table 2 Predictors of mortality and Odds Ratios for mortality were generated on raw data (OR1), after adjustment for Gender/Age/
Center/Ethnicity (OR2), after adjustment for Comorbidities (OR3) and after adjustment for disease severity (Shortness of breath/CRP/Ddimer, OR4)
Alive N (%)
Age (n = 5852)

  < 35 (n = 652)

35 to 44 (n = 612)

45 to 54 (n = 937)

55 to 64 (n = 1264)

65 to 74 (n = 1169)

  ≥ 75 (n = 1218)

Sex (n = 5852)

Female (n = 3087)

Male (n = 2765)

Admitting center (n = 5853)
Detroit (n = 3674)

New York (n = 468)

Indiana (n = 140)

Rhode Island (n = 105)

Bronx (n = 171)

Manhattan (n = 184)

Howard (n = 399)

Georgia (n = 712)

Dead N (%)

African American (n = 3662)

Latin (n = 286)

OR 2 (95% CI)

OR 3 (95% CI)

OR 4 (95% CI)

631 (12.6)

21 (2.5)

–

–

–

–

581 (11.6)

31 (3.7)

1.60 (0.91–2.82)

1.38

1.26 (0.71–2.25)

0.60 (0.23–1.55)

878(17.5)

59 (7.1)

2.02 (1,21–3.36)

1.64

1.40 (0.82–2.36)

0.84 (0.37–1.88)

1145 (22.8)

119 (14.3)

3.12 (1.94–5.02)

2.34

1.84 (1.13–3.01)

0.87 (0.40–1.86)

951 (18.9)

218 (26.2)

6.89 (4.35–10.90)

5.03

3.77 (2.34–6.08)

2.39 (1.14–4.99)

835 (16.6)

383 (46.1)

13.78 (8.78–21.64)

10.13

7.43 (4.64–11.89)

4.24 (2.04–8.80)

2726 (54.3)

361 (43.4)

–

–

–

–

2295 (45.7)

470 (56.6)

1.55 (1.33 – 1.79)

1.48 (1.26–1.74)

1.49 (1.27–1.76)

1.47 (1.17–1.84)

3267 (65.1)

407 (49)

316 (6.3)

152 (18.3)

1.56 (1.24–1.95)

3.78

4.02 (3.13–5.18)

118 (2.3)

22 (2.6)

3.86 (3.10–4.80)

1.48

1.44 (0.88–2.36)

105 (2.1)

0 (0)

1.49 (0.93–2.38)

.000

00

133 (2.6)

38 (4.6)

0.00 (0.00–0.00)

2.25

2.14 (1.44–3.19)

152 (3)

32 (3.9)

2.29 (1.57–3.33)

1.54

1.59 (1.01–2.50)

1.32 (0.62–2.82)

335 (6.7)

64 (7.7)

1.69 (1.13–2.50)

1.93

1.88 (1.35–2.62)

1.53 (1.01–2.31)

596 (11.9)

116 (14)

1.53 (1.15–2.04)

1.55

1.52 (1.19–1.94)

1.12 (0.81–1.56)

–

–

–

–

3120 (67.1)

542 (68.2)

1.12 (0.95–1.33)

1.35

1.45 (1.19–1.77)

1.47 (1.15–1.88)

Ethnicity (n = 5448)

European American (n = 1407)

OR 1 (95% CI)

1177 (25.3)

230 (28.9)

0.45 (0.29–0.71)

.97

1.06 (0.61–1.83)

0.82 (0.33–2.02)

Asian (n = 93)

265 (5.7)

21 (2.6)

0.12 (0.3–0.51)

.25

0.27 (0.06–1.13)

00

Normal (n = 1174)

946 (22)

228 (29.3)

–

–

1101 (25.6)

219 (28.2)

0.82 (0.67–1.01)

.93

Obese (n = 2579)

2249 (52.4)

330 (42.5)

0.60 (0.50–0.73)

1.02

BMI (n = 5073)

Overweight (n = 1320)

Baseline comorbidities
Cardiac Disease (n = 4141)

3148 (88.6)

447 (76)

–

–

Yes (n = 546)

No (n = 3595)

405 (11.4)

141 (24)

2.45 (197–3.04)

1.55 (1.22–1.96)

No (n = 4144)

COPD (n = 4597)

3675 (91.5)

469 (80.9)

–

–

Yes (n = 453)

342 (8.5)

111 (19.1)

2.54 (2.01–3.21)

1.62 (1.25–2.08)

No (n = 3923)

Asthma (n = 4353)

3412 (89.9)

511 (91.6)

–

–

Yes (n = 430)

383 (10.1)

47 (8.4)

0.81 (0.59–1.12)

1.01 (0.72–1.42)

No (n = 2295)

Diabetes Mellitus (n = 5436)

2073 (44.7)

222 (28)

–

–

Yes (n = 3141)

2569 (55.3)

572 (72)

1.83 (1.57–2.14)

1.59 (1.26–1.75)

No (n = 3945)

Hypertension (n = 4308)

3469 (92.3)

476 (86.9)

–

–

Yes (n = 363)

291 (7.7)

72 (13.1)

2.07 (1.76–2.45)

1.26 (1.05–1.53)

No (n = 3945)

3469 (92.3)

476 (86.9)

–

–

291 (7.7)

72 (13.1)

1.73 (1.12–2.68)

0.97 (0.72–1.30)

History of cancer (n = 4308)
Yes (n = 363)

Immune suppression (n = 1947)
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Table 2 (continued)

No (n = 1842)

Yes (n = 105)

Alive N (%)

Dead N (%)

OR 1 (95% CI)

OR 2 (95% CI)

1484 (95.3)

358 (92)

–

–

74 (4.7)

31 (8)

1.73 (1.12–2.68)

1.7 (1.12–2.79)

OR 3 (95% CI)

OR 4 (95% CI)

1.81 (1.43–2.28)

1.92 (1.53–2.40)

Presenting symptoms
Fever (n = 5442)

3269 (70.3)

541 (68.1)

–

–

Yes (n = 1632)

No (n = 3810)

1379 (29.7)

253 (31.9)

1.10 (0.94–1.30)

0.84 (0.69–1.02)

No (n = 4109)

Headache (n = 4274)

3859 (95.8)

520 (98.9)

–

–

Yes (n = 165)

159 (4.2)

6 (1.1)

0.26 (0.11–0.59)

0.49 (0.20–1.21)

No (n = 3708)

Cough (n = 5259)

3188 (70.9)

520 (68.2)

–

–

Yes (n = 1551)

1309 (29.1)

242 (31.8)

1.13 (0.96–1.33)

0.89 (0.72–1.10)

No (n = 3146)

Shortness of breath (n = 5155)

2811 (64)

335 (43.9)

–

–

Yes (n = 2009)

1581 (36)

428 (56.1)

2.27 (1.94–2.65)

1.91 (1.61–2.28)

No (n = 4125)

Chest pain (n = 4308)

3594 (95.6)

531 (96.9)

–

–

Yes (n = 183)

166 (4.4)

17 (3.1)

0.69 (0.41–1.15)

0.81 (0.47–1.40)

No (n = 4280)

Fatigue (n = 4695)

3691 (91.6)

589 (88.3)

–

–

Yes (n = 415)

337 (8.4)

78 (11.7)

1.45 (1.11–1.88)

0.68 (0.50–0.93)

No (n = 4693)

Nausea (n = 4965)

4018 (94.6)

675 (94)

–

–

Yes (n = 272)

229 (5.4)

43 (6)

1.11 (0.79–1.56)

0.74 (0.51–1.08)

No (n = 4797)

Vomiting (n = 4977)

4095 (96.2)

702 (97.5)

–

–

Yes (n = 180)

162 (3.8)

18 (2.5)

0.64 (0.39–1.06)

0.65 (0.39–1.11)

No (n = 4949)

Abdominal pain (n = 5129)

4222 (96.3)

727 (97.7)

–

–

Yes (n = 180)

163 (3.7)

17 (2.3)

0.60 (0.36–1.00)

0.58 (0.34–0.99)

No (n = 4321)

Diarrhea (n = 4636)

3707 (93.6)

614 (90.7)

–

–

Yes (n = 315)

252 (6.4)

63 (9.3)

1.50 (1.13–2.01)

1.05 (0.75–1.46)

No (n = 4852)

4154 (95.1)

698 (94.1)

–

–

216 (4.9)

44 (5.9)

1.21 (0.86–1.69)

0.92 (0.63–1.35)

Anorexia (n = 5112)
Yes (n = 260)

Laboratory Results (quartiles determined based on the entire study population;
Hemoglobin (n = 2903)
Normal (n = 1158)

1010 (40.8)

148 (34.8)

–

–

1441 (58.2)

271 (63.8)

1.28 (1.03–1.59)

1.23 (0.97–1.56)

Elevated (n = 33)

27 (1.1)

6 (1.4)

1.52 (0.62 – 3.74)

1.61 (0.62–4.18)

Normal (n = 1627)

1463 (43.5)

164 (27.3)

–

–

1857 (55.2)

419 (69.8)

2.01 (1.65–2.44)

1.63 (1.32–2.00)

Elevated (n = 62)

45 (1.3)

17 (2.8)

3.37 (1.88–6.02)

2.53 (1.35–4.75)

Normal (n = 982)

826 (53.1)

156 (45.9)

–

–

731 (46.9)

184 (54.1)

1.33 (1.05–1.68)

1.60 (1.23–2.09)

Low (n = 1712)

Lymphocyte count (n = 3965)
Low (n = 2276)

CPK (n = 1897)

Elevated (n = 915)

CRP (n = 2980)
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Table 2 (continued)
Alive N (%)
Normal (n = 187)

Elevated (n = 2793)

D-Dimer (n = 2679)

Normal (n = 449)

Dead N (%)

OR 1 (95% CI)

OR 2 (95% CI)

OR 3 (95% CI)

OR 4 (95% CI)

176 (7.2)

11 (2.1)

–

–

–

–

2279 (92.8)

514 (97.9)

3.60 (1.94–6.68)

4.00 (2.06–7.75)

3.39 (1.60–7.17)

2.78 (1.35–5.73)

433 (19.7)

16 (3.3)

–

–

–

–

Elevated (n = 2230)

1765 (80.3)

465 (96.7)

7.31 (4.28–11.8)

4.75 (2.82–8.02)

4.15 (2.44–7.05)

4.25 (2.50–7.21)

Normal (n = 1845)

Troponin (n = 2867)

1686 (70.9)

159 (32.6)

–

–

Elevated (n = 1022)

693 (29.1)

329 (67.4)

5.03 (4.08–6.20)

4.12 (3.26–5.22)

Normal (n = 1408)

Procalcitonin (n = 2491)

1266 (62.9)

142 (25.8)

–

–

Elevated (n = 1533)

1125 (47.1)

408 (74.2)

3.23 (2.62–3.97)

3.86 (3.04–4.90)

Normal (n = 862)

769 (32.1)

93 (17.9)

–

–

1598 (66.8)

423 (81.2)

2.18 (1.72–2.78)

2.32 (1.79–3.02)

Low (n = 31)

26 (1.1)

5 (1)

1.59 (0.59–4.24)

2.17 (0.76–6.22)

Normal (n = 154)

Ferritin (n = 2914)

Elevated (n = 2021)

LDH (n = 726)

141 (23.7)

13 (10)

–

–

Elevated (n = 572)

455 (76.3)

117 (90)

2.78 (1.52–5.09)

3.36 (1.77–6.37)

Normal (n = 1498)

1335 (48.4)

163 (27.2)

–

–

1421 (51.6)

437 (72.8)

2.51 (2.07–3.06)

2.63 (2.13–3.24)

AST (n = 3356)

Elevated (n = 1858)

ALT (n = 2760)

Normal (n = 2412)

Elevated (n = 348)

2004 (87.9)

163 (27.2)

277 (12.1)

437 (72.8)

Interventions

Glucocorticoids (n = 3418)

1424 (52.9)

278 (38.4)

–

–

Yes (n = 1716)

No (n = 1702)

1270 (47.1)

446 (61.6)

1.79 (1.52–2.12)

1.96 (1.61–2.39)

No (n = 4261)

3942 (92.8)

319 (45.8)

–

–

305 (7.2)

377 (54.2)

15.2 (12.6–18.4)

15.44 (12.45–19.15)

Mechanical Ventilation (n = 4943)
Yes (n = 682)

(OR = 1.7, 1.12–2.79). Among presenting symptoms
after adjusting demographics (OR2), comorbidities
(OR3), only shortness of breath was associated
with higher mortality, with OR (95% CI) of 1.91
(1.61–2.28). The presence of GI symptoms was not
associated with mortality outcomes in this study.
Several laboratory biomarkers were associated with
increased risk of death, including elevated D-dimer
(OR = 4.75, 2.82–8.02), elevated troponin (OR = 4.12,
3.26–5.22), lymphocytopenia (OR = 1.63, 1.32–2.00)
or elevated lymphocytosis (OR = 2.53, 1.35–4.75),
elevated CPK (OR = 1.60, 1.23–2.09), elevated
CRP (OR = 4.00, 2.06–7.75), elevated procalcitonin
(OR = 3.86, 3.04–4.90), elevated ferritin (OR = 2.32,

1.79–3.02), elevated LDH (OR = 3.36, 1.77–6.37), and
elevated AST (OR = 2.63, 2.13–3.24). As for treatment
interventions, glucocorticoid use was associated with a
OR of 1.96 (1.61–2.39) for mortality from COVID-19
after adjusting for age/gender/race/center. In patients
receiving mechanical ventilation, the OR for COVID19 mortality was 15.44 (12.45–9.15) (Table 2).

Discussion
The spectrum of COVID-19 disease ranges from
asymptomatic to mild to severe, with the latter requiring
hospitalization. In the early phases of the pandemic,
severe COVID-19 disease often led to death. In this
study, we collected data from 8 hospitals across the
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US with the goal of characterizing overall features and
predictors of COVID-19 mortality among racially and
ethnically diverse population. Our cohort consisted
of 65% AA, 24.9% EA, 5% LAT, and 1.6% AS patients,
with an overall 14.5% mortality. Among this cohort, we
identified and verified predictors of death from COVID19, including older age, male sex, comorbidities such as
cardiac disease, COPD, diabetes mellitus, hypertension,
and immune suppression, and respiratory symptoms like
shortness of breath. Many of these factors such as older
age [16], male sex [17], African American race [16, 18]
and presence of comorbidities [16] have been previously
identified in other studies for higher risk of mortality
from COVID-19.
Although our cohort showed more females
hospitalized, mortality was higher for males. This is
consistent with other published data [6, 19, 20] and is
likely due to gender differences in the level of expression
of ACE2 and TMPRSS2 [17]. These two virulent factors
are required by SARS-CoV-2 to gain entry into human
cells for infection. EA had the highest mortality rate
of 17% vs. 14.8% for AAs and 7.3% for LAT. This high
death rate in EA (oldest group in our study) is further
confirmed when OR for death were established for 6
age categories. The two age categories above 65 years
maintained a high OR for death, even after multiple
adjustments (Table 2). LAT were the youngest group in
our study and had the lowest death rate of 7.3%. El Chaar
et al.[21], reported increased death rates among AA and
LAT in New York (Bronx—22.8% and Brooklyn—19.8%).
These death rates are higher than our study results. This
is probably secondary to the demographic variation of
the locality, while ours consists of a large cohort that
represents a national sample. The LAT patients in our
study were the youngest and had the lowest mortality
rate when compared to AA and EA. Greene et al.
[22] reported decreasing age of SARS-CoV-2 positive
patients in early versus later months of the pandemic,
due primarily to increased testing and the fact that their
study was on outpatients. When considering inpatients,
as is the case in our study, we need to interpret the young
age of the LAT as an indicator of higher exposure of this
population, through living conditions and occupations
in essential jobs that do not benefit from remote work
protections that other populations have access to. This is
further confirmed by the fact that EA in our cohort had
the highest mortality which was associated with older age
when compared to either one of the other racial groups.
When adjusting for age, gender, and centers (OR2), EA
had a higher OR of poor outcome when compared to AA,
pointing to unknown genetic factors that might increase
the risk of disease severity in this group.
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Comorbidities also prove to be a risk factor for
COVID-19 mortality. Primarily, a patient’s susceptibility
to SARS-CoV-2 may depend on a higher expression
of ACE2, which has been found in patients with
hypertension and cardiovascular disease [23]. Our study
showed presence of pre-existing cardiovascular disease
and hypertension was associated with poor out-comes in
COVID-19 patients. Elevated plasma ACE2 activity is an
independent predictor of major cardiac events associated
with cardiovascular disease development, and ACE2
was found in carotid atherosclerosis and abdominal
aortic aneurysm [24, 25]. Another mechanism that
could affect the cardiovascular and other body systems
during the COVID-19 pandemic is the acute systemic
inflammatory response caused by the uncontrolled
release of pro-inflammatory cytokines. The ACE2-related
mechanism, Matrix-metalloproteinases control systems
and cytokine levels are dysregulated in cardiovascular
disease and COVID-19 [26]. This combined effect results
in adverse clinical outcomes in COVID-19 patients with
pre-existing cardiac diseases. Comorbid background
allows progression of the disease to multi-system organ
failure for eventual death of severe COVID-19 [27].
Comorbidities tend to be higher among AA populations,
a set up for COVID-19 infection [16]. Here, these
comorbidities also prove to be a risk factor for COVID19 mortality. Comorbid background allows progression
of the disease to multi-system organ failure for eventual
death of severe COVID-19. Certain comorbidities such
as asthma and diabetes mellitus lead to increased ACE2
and TMPRSS2 expression in lung cells [28]. Published
data demonstrate that AA have twice the rate of
hospitalization for Covid-19 compared to Whites [16].
However, once hospitalized (meaning severe COVID-19),
there is no difference in death rates based on two large
studies [29, 30]. Interestingly, in our cohort, we observed
the highest mortality among AA and EA. EA patients
were older in our cohort, which may have contributed to
excess deaths in this group, as age is a strong predictor
of death from COVID-19. After we adjusted for
comorbidities, AAs had the highest risk of COVID-19
death. We did not find any correlation BMI and COVID19 death.
In this study, Mortality rates were higher among
patients in New York compared to other geographic
locations. The crude fatality rate was 9.2% overall and
32.1% among hospitalized patients. New York was at the
forefront of this pandemic and had limited resources
at the time of data accrual, which could explain the
differences in mortality rate. The high OR for COVID-19
death in New York relative to other locations also likely
reflects existing health disparity.
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There are mixed opinions regarding the usage of
steroids in the treatment of COVID-19 patients.
Glucocorticoid usage was associated with an increased
risk of COVID-19 death in our cohort. This could
be due to the inhibition of immune surveillance by
corticosteroid leading to more persistent SARS-CoV-2
infection and higher viral load. While some studies
have mentioned that glucocorticoids are used more
routinely and are shown to be effective in treating
severe COVID-19 patients and showed a reduction in
the need for mechanical ventilation since the beginning
of the pandemic [31, 32], other studies mentioned that
corticosteroid use in critically ill COVID-19 patients was
associated with a much higher case fatality rate [33, 34].
Glucocorticoid treatment delayed viral clearance and
increase in secondary infections in COVID-19 patients of
taking high doses or medium doses instead of low doses
of glucocorticoids [31, 33]. We recommend judicious
use of glucocorticoids in mild to moderate COVID-19
patients.
One of the unique aspects of our study is the inclusion
of serum biomarkers with comprehensive symptomatic,
clinical, as well as racial and ethnic information. Anemia,
as well as lymphopenia and lymphocytosis reflect bone
marrow effects due to acute viral infection. Anemia
can exacerbate hypoxia among COVID-19 patients
[35]. COVID-19 is a systemic inflammatory disease,
and we identified several inflammatory markers and
acute phase reactants as risk, including C-reactive
protein, procalcitonin, and ferritin. COVID-19 creates a
prothrombotic milieu or results in a prothrombotic, and
consistent with this, we noted high risk for death with
elevation of D-dimers. SARS-CoV-2 can infect other
organs besides the lung, as well as can cause secondary
injury to organs as a result of respiratory failure [35–38].
We noted elevated risk of death from COVID-19 when
patients had elevated troponins, indicating heart muscle
damage. Heart muscle, as well as skeletal muscle, can
release CPK and AST, and elevation of both individually
was associated with increased risk of death. Liver
inflammation can occur with COVID-19, but may be
a bystander effect that is not necessarily a contributor
towards COVID-19 mortality [39]. In our cohort, we did
not observe a risk of death with elevation of ALT, which
is more specific to the liver. Elevation of LDH, a marker
of tissue damage from metabolic dysfunction, was also
associated with risk of COVID-19 death.
We note some differences in prevalence and frequency
of clinical presentation of severe COVID-19 among
hospitalized patients. AAs had the highest prevalence
of comorbidities and inflammatory markers, and LAT
patients had the highest prevalence of symptoms. It is
unclear why there might be differences in presentation,
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particularly for symptoms, between certain races/
ethnicities. While there is evidence that comorbidities
may foster increased ACE2 and TMPRSS2 expression
leading to higher chance for SARS-CoV-2 infection
loads [28], it does not necessarily explain symptomology
differences. We do not know if there is biology behind
the differences or cultural.
This study has some limitations. That is retrospective
and the fact that it involves areas in the US that were hit by
the pandemic at different times. This might have affected
our findings as the New York area that was hit first and
hard by the pandemic displayed higher mortalities
than other regions that might have had more time
understanding and better managing COVID-19 patients
for better outcome. There was a lack in some laboratory
parameters such as LDH, CPK, and procalcitonin from
all the centers. So, the analysis of these factors associated
with outcomes probably suffered from confusion bias.
However, the analyses were consistent with what was
known elsewhere, and this external consistency has the
benefit of increasing confidence that the data are robust.
It is therefore believed that the main results, which are
the overall and group mortality rates are plausible.

Conclusions
Our study encompasses symptomatic, clinical, and
biomarker associations among races/ethnicities for
COVID-19 death. Our cohort was enriched for AA
patients by virtue of the 8 hospitals that could provide
information for this study. We identify and verify several
aspects for risk of COVID-19 death, and enhance, and
enrich the literature with simultaneous associations
from serum biomarkers that can add to improve patient
care for prediction of death from COVID-19. We
recommend special attention is required in treating
COVID-19 African American Population. Priority should
be given to patients with elevated inflammatory markers,
preexisting conditions and elevated liver enzymes. We
also recommend judicious use of glucocorticoids in mild
to moderate COVID-19 hospitalized patients.
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